Table 4 Overall survival in relation to standard clinicopathological prognostic factors and the studied markers

Age

   <47

68%

1

0.99, 1.02

0.880

   ≥ 47 *

66%

Sex:

Male (42)

59%

1.1

0.85, 1.04

0.652

Female (17)

64%

Tumor type

SCC (27)

60%

1.212,

0.538, 2.734

0.643

TCC (27)

65%

Adenocarcinoma (5)

60%

Tumor grade

I (5)

66%

1.96

1.66, 21.331

<0.000

4.350

1.786, 10.591

0.001

II (39)

32%

III (15)

11%

Lymph Node Involvement:

1.099

0.423, 2.859

0.846

Positive (10)

49%

Negative (49)

55%

Metastatic recurrence:

No (33)

58%

14.149

5.117, 39.123

0.000

14.903

5.315, 41.785

0.000

Yes (21)

25%

Pathological Stage:

p2 & pp3a (27)

49%

1.341

0.575, 3.127

0.498

p3b &p4 (32)

35%

Nm23 (IHC )

Positive (34)

66.5%

1.62

0.535, 2.244

0.345

Negative (25)

59.6%

nm23(RNA )

   Positive (33)

64.8%

1.34

1.20, 1.50

0.021

0.695

0.586, 1.975

0.444

   Negative (19)

35.5%

EGFR (IHC)

   Positive (39)

41%

1.61

1.04, 2.29

0.034

3.576

1.206, 10.602

0.022

   Negative (20)

69%

EGFR (RNA)

   Positive (32)

39%

1.69

1.16, 2.74

0.031

3.911

1.148, 8.511

0.025

   Negative (20)

69%

Rb

   Positive (25)

54%

1.1

0.27, 1.76

0.287

   Negative (34)

49%

p53 (IHC)

   Positive (21)

29%

3.9

2.281, 12.42

0.011

2.512

0.948, 6.662

0.64

   Negative (38)

60%

P53 (mutations)

   Positive (8)

0.539

   Negative (51)

Number of abnormal genes

1.70

1.20, 5.90

0.022

7.331

2.696, 12.940

0.001

   <2

   ≥ 2